RayzeBio
RayzeBio

BMS Expands Oncology Portfolio with $41bn RayzeBio Acquisition
BIOT
💼 Bristol Myers Squibb (BMS) acquires RayzeBio for $4.1bn, expanding its oncology portfolio with targeted radiopharmaceuticals. ⚕️🎯
RayzeBio

💼 Bristol Myers Squibb (BMS) acquires RayzeBio for $4.1bn, expanding its oncology portfolio with targeted radiopharmaceuticals. ⚕️🎯